On September 22, 2026, James Wyper notified the Board of Directors (the "Board") of Lineage, Inc. (the “Company”) of his resignation as a director of the Company, effective immediately.
On September 23, 2026, Mr. Thattai and the Company mutually determined that Mr. Thattai's Chief Transformation Officer responsibilities would be transitioned to other members of management, effective September 28, 2026 (the “Transition Date”).
On September 23, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Paul Beiboer as a director of the Company, effective immediately, to fill the vacancy on the Board created by Mr. Wyper's resignation.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
James Wyper resigned as Director at Lineage, Inc..
Action
resigned
Role
Director
Exact text from the filing
On September 22, 2026, James Wyper notified the Board of Directors (the "Board") of Lineage, Inc. (the “Company”) of his resignation as a director of the Company, effective immediately.
Sudarsan Thattai departed as Chief Transformation Officer at Lineage, Inc..
Action
stepped down
Role
Chief Transformation Officer
Exact text from the filing
On September 23, 2026, Mr. Thattai and the Company mutually determined that Mr. Thattai's Chief Transformation Officer responsibilities would be transitioned to other members of management, effective September 28, 2026 (the “Transition Date”).
Paul Beiboer was appointed as Director at Lineage, Inc..
Action
appointed
Role
Director
Exact text from the filing
On September 23, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Paul Beiboer as a director of the Company, effective immediately, to fill the vacancy on the Board created by Mr. Wyper's resignation.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.